Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Prokidney (PROK) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Prokidney (PROK) over the last 4 years, with Sep 2025 value amounting to -$35.8 million.

  • Prokidney's Net Income towards Common Stockholders rose 12.69% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.2 million, marking a year-over-year decrease of 16.60%. This contributed to the annual value of -$61.2 million for FY2024, which is 72.51% down from last year.
  • Latest data reveals that Prokidney reported Net Income towards Common Stockholders of -$35.8 million as of Q3 2025, which was up 3.04% from -$37.0 million recorded in Q2 2025.
  • Over the past 5 years, Prokidney's Net Income towards Common Stockholders peaked at -$14.4 million during Q4 2022, and registered a low of -$67.5 million during Q1 2022.
  • For the 3-year period, Prokidney's Net Income towards Common Stockholders averaged around -$37.2 million, with its median value being -$37.0 million (2025).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first spiked by 45.31% in 2023, then tumbled by 123.18% in 2024.
  • Quarterly analysis of 4 years shows Prokidney's Net Income towards Common Stockholders stood at -$14.4 million in 2022, then crashed by 50.86% to -$21.7 million in 2023, then tumbled by 123.18% to -$48.5 million in 2024, then rose by 12.69% to -$35.8 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$35.8 million for Q3 2025, versus -$37.0 million for Q2 2025 and -$38.0 million for Q1 2025.